A smaller study from Chicago, Illinois, reported 142 patients with EGFR-positive NSCLC contrasted against 140 patients with wildtype EGFR NSCLC and found no difference in 5-year recurrence rates, although patients with EGFR-positive NSCLC had higher rates of metastatic recurrence.4 Mature survival outcomes were not reported owing to insufficient follow-up. This evidence concerns the gene EGFR and non-small cell lung carcinoma.